Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
Primary Purpose
Parkinson Disease, Constipation
Status
Completed
Phase
Phase 3
Locations
Malaysia
Study Type
Interventional
Intervention
Probiotics with prebiotic
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson's disease, Constipation, Probiotics, Prebiotic, Gut transit time, Motor outcome, NMSS, PDQ39, Randomised controlled trial
Eligibility Criteria
Inclusion Criteria:
- Age 18 or older; were diagnosed with idiopathic PD
- PD with Hoehn and Yahr stages 1-4,
- Fulfilled the Rome III criteria for functional constipation
Exclusion Criteria:
- MMSE score of ≤ 21/30
- Positive stool occult blood screening
- Diagnosis of secondary parkinsonism
- Previous history of small and large bowel disease
- History of gastrointestinal tract surgery
- Use of probiotics or antibiotics two weeks prior to baseline visit
- Been on medications such as antidepressants or anticholinergics
- History of lactose intolerance
- Concomitant diagnosis of hypothyroidism and diabetes mellitus.
Sites / Locations
- Hospital Canselor Tuanku Muhriz, UKM Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Probiotic with prebiotic
Placebo
Arm Description
Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
Outcomes
Primary Outcome Measures
constipation symptoms
The presence of constipation symptoms at baseline and at 8 weeks evaluated by
Garrigues Questionnaire (GQ).GQ is a 21-item self-reported screening questionnaire to detect the presence of constipation symptoms, using two different sets of four-point Likert scale responses.Although 12 items assess bowel habits, 9 items specifically assess constipation symptoms and were used in our evaluation: (i)Feeling of blockage in the anus;(ii) Need to press around anus/vagina to complete bowel movement; (iii) Spend >10 minutes to pass stool;(iv) Straining during bowel movement;(v) Feeling of hard stool;(vi) Feeling of incomplete emptying sensation; (vii)Bowel opening frequency;(viii) Frequency of oral laxative use;(ix) Frequency of enema use
Secondary Outcome Measures
Whole Gut Transit Time (WGTT) in hours
WGTT was measured at baseline and at the end of 8 weeks, using red carmine capsule. The mean change in the WGTT (WGTT 8 weeks - WGTT baseline) was compared between the two groups.
Frequency of patients with constipation (Bowel motion < 3 per week) in percentage
Based on the stool diary, the percentage of patients who experienced less than 3 BM per week was calculated at baseline and at the end of study.
Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part 11
This measures the motor aspects of activity of daily living and consists of 13 items with scores between 0- 52. This instrument is given at baseline and 8 weeks. Lower score indicates low severity
Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part 111
This measures the seveirty of motor symptoms using 18 items (score 0-72). This instrument is given at baseline and 8 weeks. Lower score indicates low severity.
Non motor symptom score
Change in non-motor symptoms severity scores using the Non motor Symptom Scale (NMSS) which consists of 9 domains (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucination, attention/memory, gastrointestinal tract, urinary, sexual function and miscellaneous.Score ranges from minimum of 3 to 360. Lower score indicates lower severity
Parkinsons Disease Quality of Life -39 Summary Index (PDQ39SI)
Change in PD9 39-SI which measure 8 domains of Quality of Life ( Lower score indicates better quality of life)
Weight in kilogram
Change in body weight measurement in Kg
Height in metres
Height will be measured in meters at baseline
Body Mass Index (kg/m2)
Weight and height will be combined to report BMI in kg/m^
Full Information
NCT ID
NCT04451096
First Posted
June 19, 2020
Last Updated
June 25, 2020
Sponsor
National University of Malaysia
1. Study Identification
Unique Protocol Identification Number
NCT04451096
Brief Title
Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
Official Title
Probiotics-prebiotic Fiber Therapy Improved Bowel Opening Frequency and Whole Gut Transit Time in Parkinson's Disease Patients With Constipation: A Randomised Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
October 6, 2018 (Actual)
Primary Completion Date
February 28, 2019 (Actual)
Study Completion Date
February 28, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National University of Malaysia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A double blinded randomised placebo controlled trial to evaluate the efficacy of probiotics on constipation symptoms and whole gut transit time in patients with Parkinson's disease.PD patients with constipation were randomized to receive a multi-strain probiotic (Lactobacillus spp and Bifidobacterium spp at 30 X 109 CFU) with fructo-oligosaccaride (FOS) or placebo (fermented milk) twice daily for 8 weeks. Primary outcomes include changes in the presence of constipation symptoms using 9 items of Garrigues Questionnaire (GQ), which included an item on bowel opening frequency. Secondary and exploratory outcomes include whole gut transit time (WGTT), quality of life (PDQ39-SI), motor (MDS-UPDRS) and non-motor symptoms (NMSS).
Detailed Description
This was an eight-week double-blind, randomized placebo-controlled intervention study involving 55 idiopathic PD patients attending tertiary hospital. This study was conducted in accordance with good clinical practice as per Declaration of Helsinki and was approved by the institution's Research and Ethics Committee (FF-2018-387). Written informed consent was obtained from all particpants prior to enrollment.
Participants were included if they were aged 18 or older; were diagnosed with idiopathic PD in Hoehn and Yahr stages 1-4, and fulfilled the Rome III criteria for functional constipation which requires the presence of recurrent abdominal pain 3 days per month in the last 3 months, and symptom onset 6 months prior to diagnosis, with additional criteria below to be fulfilled, as adapted from Longstreth, et al12.
Must include two or more of the following:
Straining during at least 25% of defecations
Lumpy or hard stools in at least 25% of defecations
Sensation of incomplete evacuation for at least 25% of defecations d. Sensation of anorectal obstruction/blockage for at least 25% of defecations
e. Manual maneuvers to facilitate at least 25% of defecations (e.g, digital evacuation, support of the pelvic floor) f. Fewer than 3 defecations per week
Loose stools are rarely present without the use of laxatives
There are insufficient criteria for IBS
Participants were excluded if they had: a MMSE score of ≤ 21/30; a positive stool occult blood screening; a diagnosis of secondary parkinsonism; previous history of small and large bowel disease; prior history of gastrointestinal tract surgery; use of probiotics or antibiotics two weeks prior to baseline visit; been on medications such as antidepressants or anticholinergics; history of lactose intolerance; concomitant diagnosis of hypothyroidism and diabetes mellitus.
All participants were assessed at baseline and at 8 weeks following intervention for all outcome assessments. At baseline, additional data on demographics (age, sex, educational level), duration of PD, dopaminergic medication, Hoehn & Yahr Scoring during ON period, and the level of physical activity were recorded at baseline. A sedentary behaviour was defined as being physically active < 4 hours /week.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Constipation
Keywords
Parkinson's disease, Constipation, Probiotics, Prebiotic, Gut transit time, Motor outcome, NMSS, PDQ39, Randomised controlled trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
placebo controlled
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
double blinded
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Probiotic with prebiotic
Arm Type
Active Comparator
Arm Description
Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics with prebiotic
Other Intervention Name(s)
Multistrain Probiotics with prebiotic
Intervention Description
Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
Granulated milk products
Intervention Description
Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
Primary Outcome Measure Information:
Title
constipation symptoms
Description
The presence of constipation symptoms at baseline and at 8 weeks evaluated by
Garrigues Questionnaire (GQ).GQ is a 21-item self-reported screening questionnaire to detect the presence of constipation symptoms, using two different sets of four-point Likert scale responses.Although 12 items assess bowel habits, 9 items specifically assess constipation symptoms and were used in our evaluation: (i)Feeling of blockage in the anus;(ii) Need to press around anus/vagina to complete bowel movement; (iii) Spend >10 minutes to pass stool;(iv) Straining during bowel movement;(v) Feeling of hard stool;(vi) Feeling of incomplete emptying sensation; (vii)Bowel opening frequency;(viii) Frequency of oral laxative use;(ix) Frequency of enema use
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Whole Gut Transit Time (WGTT) in hours
Description
WGTT was measured at baseline and at the end of 8 weeks, using red carmine capsule. The mean change in the WGTT (WGTT 8 weeks - WGTT baseline) was compared between the two groups.
Time Frame
8 weeks
Title
Frequency of patients with constipation (Bowel motion < 3 per week) in percentage
Description
Based on the stool diary, the percentage of patients who experienced less than 3 BM per week was calculated at baseline and at the end of study.
Time Frame
8 weeks
Title
Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part 11
Description
This measures the motor aspects of activity of daily living and consists of 13 items with scores between 0- 52. This instrument is given at baseline and 8 weeks. Lower score indicates low severity
Time Frame
8 weeks
Title
Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part 111
Description
This measures the seveirty of motor symptoms using 18 items (score 0-72). This instrument is given at baseline and 8 weeks. Lower score indicates low severity.
Time Frame
8 weeks
Title
Non motor symptom score
Description
Change in non-motor symptoms severity scores using the Non motor Symptom Scale (NMSS) which consists of 9 domains (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucination, attention/memory, gastrointestinal tract, urinary, sexual function and miscellaneous.Score ranges from minimum of 3 to 360. Lower score indicates lower severity
Time Frame
8 weeks
Title
Parkinsons Disease Quality of Life -39 Summary Index (PDQ39SI)
Description
Change in PD9 39-SI which measure 8 domains of Quality of Life ( Lower score indicates better quality of life)
Time Frame
8 weeks
Title
Weight in kilogram
Description
Change in body weight measurement in Kg
Time Frame
8 weeks
Title
Height in metres
Description
Height will be measured in meters at baseline
Time Frame
Baseline
Title
Body Mass Index (kg/m2)
Description
Weight and height will be combined to report BMI in kg/m^
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 or older; were diagnosed with idiopathic PD
PD with Hoehn and Yahr stages 1-4,
Fulfilled the Rome III criteria for functional constipation
Exclusion Criteria:
MMSE score of ≤ 21/30
Positive stool occult blood screening
Diagnosis of secondary parkinsonism
Previous history of small and large bowel disease
History of gastrointestinal tract surgery
Use of probiotics or antibiotics two weeks prior to baseline visit
Been on medications such as antidepressants or anticholinergics
History of lactose intolerance
Concomitant diagnosis of hypothyroidism and diabetes mellitus.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Norlinah Mohamed Ibrahim, MBBChMRCP
Organizational Affiliation
National University of Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Canselor Tuanku Muhriz, UKM Medical Center
City
Kuala Lumpur
ZIP/Postal Code
56000
Country
Malaysia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
We'll reach out to this number within 24 hrs